{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T11:42:26Z","timestamp":1786448546032,"version":"build-2736575974"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T00:00:00Z","timestamp":1659657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To compare cumulative live birth rates and perinatal outcomes of young IVF\/ICSI patients with low anti-Mullerian hormone (AMH) levels on a gonadotropin-releasing hormone antagonist (GnRH-ant) regimen with those on a high progesterone state of ovulation (PPOS) regimen.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retrospectively analyzed 798 patients who underwent <jats:italic>in vitro<\/jats:italic> fertilization (IVF) or intracytoplasmic sperm microinjection (ICSI) between January 2015 and December 2020 at the Third Affiliated Hospital of Zhengzhou University. A total of 798 cycles of complete clinical data from patients who underwent <jats:italic>in vitro<\/jats:italic> fertilization (IVF) or intracytoplasmic sperm injection (ICSI) at the Reproductive Medicine Center of Zhengzhou University Hospital between January 2015 and December 2020 and were eligible for AMH &amp;lt; 1.2 ng\/ml at age &amp;lt; 35 years, Group A1: very low AMH levels (AMH &amp;lt; 0.5 ng\/mL) and GnRH antagonist regimen; Group A2, very low AMH level (AMH &amp;lt; 0.5 ng\/mL) and PPOS regimen; Group B1, low AMH level (0.5 ng\/mL \u2264 AMH &amp;lt; 1.2 ng\/mL) and GnRH antagonist regimen; and Group B2, low AMH level (0.5 ng\/mL \u2264 AMH &amp;lt; 1.2 ng\/mL), and the PPOS regimen.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At very low levels of AMH (&amp;lt; 0.5 ng\/mL), the CLBR of the GnRH antagonist regimen was not significantly different from that of the PPOS regimen (P &amp;gt; 0.05), at 0.5 ng\/mL \u2264 AMH &amp;lt; 1.2 ng\/mL. Statistics showed that the CLBR of the GnRH antagonist regimen was significantly higher than that of the PPOS regimen (49.7% vs. 35.7%, P=0.002). Logistic regression analysis showed that in Group A: the younger the female partner, the higher the CLBR (OR = 0.972, 95% CI = 0.923\u20131.042, P = 0.022), and the more the AFC, the higher the CLBR (OR = 1.166, 95% CI = 1.091\u20131.336, P &amp;lt; 0.001). Group B: the higher the number of good-quality embryos, the higher the CLBR (OR = 2.227, 95% CI = 1.869\u20132.654, P &amp;lt; 0.001). Compared with PPOS regimens, the antagonist regimen was able to increase the CLBR. The analysis of Group A showed that the antagonist regimen had a shorter TTP than the PPOS regimen (P &amp;lt; 0.001); however, the PPOS regimen had a lower cost of ovulation (4311.91 vs. 4903.81, P = 0.023). The antagonist regimen in Group B had a shorter TTP than the PPOS regimen, and there was no significant difference in the cost of ovulation. In the analysis of perinatal outcomes, there were no statistically significant differences in preterm birth, low birth weight, very low birth weight, and pregnancy complications among the four groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Young patients with very low AMH levels (&amp;lt; 0. 5 ng\/mL), the GnRH antagonist regimen was comparable to the PPOS regimen in CLBR outcomes; the antagonist regimen shortens the time to clinical pregnancy, and the PPOS regimen is more cost-effective. In young patients with low AMH levels of 0.5 ng\/mL and &amp;lt;1.2 ng\/mL, the GnRH antagonist regimen can more appropriate to improve CLBR, and the perinatal outcomes were similar for both regimens.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2022.938500","type":"journal-article","created":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T10:01:23Z","timestamp":1659693683000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Analysis of cumulative live birth rate and perinatal outcomes in young patients with low anti-m\u00fcllerian hormone levels using two ovulation promotion protocols: A cohort study"],"prefix":"10.3389","volume":"13","author":[{"given":"Zhen","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruolin","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingnan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichun","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1093\/humupd\/dmq034","article-title":"AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation: A meta-analysis","volume":"17","author":"Broer","year":"2011","journal-title":"Hum Reprod Update"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmz046","article-title":"Adjuvant treatment strategies in ovarian stimulation for poor responders undergoing IVF: A systematic review and network meta-analysis","volume":"26","author":"Zhang Y","year":"2020","journal-title":"Hum Reprod Update"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1080\/09513590.2018.1505850","article-title":"Women with extreme low AMH values could have in vitro fertilization success","volume":"35","author":"Sefrioui","year":"2019","journal-title":"Gynecol Endocrinol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmw001","article-title":"Trends in \u2018poor responder\u2019 research: lessons learned from RCTs in assisted conception","volume":"22","author":"Papathanasiou","year":"2016","journal-title":"Hum Reprod Update"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/09513590.2017.1416464","article-title":"A comparison of treatment results of the different treatment protocols in patients with poor ovarian response","volume":"34","author":"Sanverdi","year":"2018","journal-title":"Gynecol Endocrinol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e14379","DOI":"10.1097\/MD.0000000000014379","article-title":"The incidence of unexpected poor ovarian response in Chinese young women","volume":"98","author":"Zhuang","year":"2019","journal-title":"Medicine"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0104779","article-title":"Birth weight reference percentiles for Chinese","volume":"9","author":"Dai","year":"2014","journal-title":"PloS One"},{"key":"B8","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1111\/j.1600-0412.2011.01088.x","article-title":"Maternal and child outcome after in vitro fertilization\u2013a review of 25 years of population-based data from Sweden","volume":"90","author":"Finnstr\u00f6m","year":"2011","journal-title":"Acta Obstet Gynecol Scand"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2005.00745.x","article-title":"In vitro fertilisation in Sweden: obstetric characteristics, maternal morbidity and mortality","volume":"112","author":"K\u00e4LL\u00e9n","year":"2005","journal-title":"Bjog"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0803072","article-title":"Cumulative live-birth rates after In vitro fertilization","volume":"360","author":"Malizia","year":"2009","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"699","DOI":"10.3760\/cma.j.issn.2096-2916.2019.09.002","article-title":"Factors influencing cumulative live birth rate after in vitro fertilization in patients with ovarian hyporesponsiveness","volume":"9","author":"Xu","year":"2019","journal-title":"Chin J Reprod Contraception"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dem270","article-title":"Are GnRH antagonists comparable to agonists for use in IVF","volume":"22","author":"Huirne","year":"2007","journal-title":"Hum Reprod"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.702558","article-title":"Progestin-primed ovarian stimulation protocol for patients in assisted reproductive technology: A meta-analysis of randomized controlled trials","volume":"12","author":"Guan","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"hoaa009","DOI":"10.1093\/hropen\/hoaa008.eCollection2020","article-title":"ESHRE guideline: ovarian stimulation for IVF\/ICSI(\u2020)","volume":"2","author":"Bosch","year":"2020","journal-title":"Hum Reprod Open"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.705264","article-title":"Comparison of the cumulative live birth rates of progestin-primed ovarian stimulation and flexible GnRH antagonist protocols in patients with low prognosis","volume":"12","author":"Du","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00796","article-title":"Progestin vs. gonadotropin-releasing hormone antagonist for the prevention of premature luteinizing hormone surges in poor responders undergoing in vitro fertilization treatment: A randomized controlled trial","volume":"10","author":"Chen","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1093\/humupd\/dmaa040","article-title":"Progestins for pituitary suppression during ovarian stimulation for ART: A comprehensive and systematic review including meta-analyses","volume":"27","author":"Ata","year":"2021","journal-title":"Hum Reprod Update"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dev270","article-title":"How do cumulative live birth rates and cumulative multiple live birth rates over complete courses of assisted reproductive technology treatment per woman compare among registries","volume":"31","author":"De Neubourg","year":"2016","journal-title":"Hum Reprod"},{"key":"B19","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.fertnstert.2015.03.022","article-title":"Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization","volume":"104","author":"Kuang","year":"2015","journal-title":"Fertil Steril"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.rbmo.2018.12.044","article-title":"Evaluation of the cost-effectiveness of ovulation suppression with progestins compared with GnRH analogs in assisted reproduction cycles","volume":"38","author":"Evans","year":"2019","journal-title":"Reprod BioMed Online"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/422656a","article-title":"Fertility treatments: seeds of doubt","volume":"422","author":"Powell","year":"2003","journal-title":"Nature"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.938500\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T10:01:25Z","timestamp":1659693685000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.938500\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,5]]},"references-count":21,"alternative-id":["10.3389\/fendo.2022.938500"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.938500","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,5]]},"article-number":"938500"}}